Avacta Group plc (AIM: AVCT), a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer® and pre|CISION™ platforms.
Omega Diagnostics Gp (AIM:ODX) Change of preliminary results date
Change of preliminary results date and investor presentation and update to CD4 sale
Omega Diagnostics Gp (AIM:ODX) Completion of Sale of the CD4 Business
Completion of Sale of the CD4 Business
Novacyt S.A. (AIM:NCYT) Launch of research-use-only adenovirus F41 assay
The assay has been developed by Novacyt to support research efforts following a recent increase in cases of acute hepatitis in children
Novacyt S.A. (AIM:NCYT) Approval of exsigT COVID-19 Direct test in the UK
Approval of exsig™ COVID-19 Direct test in the UK under CTDA legislation
Novacyt S.A. (AIM:NCYT) Trading update and progress against strategy
Trading update and progress against strategy for H1 2022
Oxford BioDynamics (AIM:OBD) US reimbursement code for EpiSwitch® CiRT
Issued US reimbursement code for Checkpoint Inhibitor Response Test (EpiSwitch® CiRT)
Omega Diagnostics Heads of Terms agreed for Sale of CD4 Busines
Omega Diagnostics Group PLC, (AIM: ODX). announced that it has selected a preferred bidder for its CD4 business after having made an announcement nearly two months back.
Avacta Group PLC (AIM:AVCT) Second dose escalation in phase 1 trial of AVA6000
Avacta announces second dose escalation in the Phase I clinical study of AVA6000 Pro-doxorubicin
Novacyt S.A. (AIM:NCYT) Launch of monkeypox assay
Paris, France and Camberley, UK – 28 June 2022 – Novacyt ( EURONEXT GROWTH: ALNOV; AIM: NCYT ), an international specialist in clinical diagnostics, announces the launch of its research-use-only
Novacyt S.A. (AIM:NCYT) DHSC dispute update
Paris, France and Camberley, UK – 16 June 2022 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces an update on its ongoing dispute with
